The AI model ARTIMES measures tumor volume rather than diameter, allowing for more accurate predictions of patient survival. This enables physicians to make informed decisions about treatment, potentially leading to improved patient outcomes and reduced healthcare costs.
A large DRUP trial reveals that existing targeted cancer therapies can deliver profound and durable benefits, even in heavily pretreated or rare cancers. About one-third of patients responded to treatment or had stable disease for at least four months.
Researchers at the Netherlands Cancer Institute developed a deep learning model PARM that predicts gene regulation with unprecedented accuracy. The model enables the prediction of functional impact of regulatory mutations in specific cell types, opening new paths for cancer diagnostics and patient stratification.
The SONIA trial found that delaying and shortening CDK4/6 inhibitor treatment in patients with hormone receptor-positive advanced breast cancer leads to similar survival outcomes while reducing toxicity and cost by €45 million per year. This innovative approach could reduce the burden on healthcare systems worldwide.
Researchers have shown that cancer cells can modify their ribosomes to become less visible to the immune system, allowing them to evade detection. This discovery could lead to new cancer therapies by making these cells more visible to the immune system.
A short course of immunotherapy prior to surgery was highly effective in treating colon cancer, with 95% of patients showing significant tumor reduction or complete elimination. The treatment also showed promising results in preventing cancer recurrence and metastasis over a two-year follow-up period.
The NADINA trial found that 59% of patients responded well to neoadjuvant immunotherapy before surgery, allowing them to forgo adjuvant treatment. This treatment approach also showed rapid effects, with 95% of patients remaining tumor-free after just six weeks.
Researchers found a new pathway to cancer cell death led by the Schlafen11 (SLFN11) gene. This discovery could have implications for cancer treatment and patient outcomes.
A study published in Cell reveals a detailed catalogue of bacteria living in cancer metastases, including links to therapy efficacy and tumor cell activity. The research provides new insights into how bacteria interact with cancer cells and their surroundings.
Researchers have developed a new strategy to combat cancer by activating oncogenic signaling in cancer cells, leading to their exhaustion. The approach has shown promising results in animal studies, with minimal side effects.
A new stool test, multitargetFIT-test (mtFIT), detects cancer precursors more effectively than the current FIT test, predicting a reduction in new cases of colorectal cancer and mortality. The new test yields more true-positive results without an increase in 'false-positive' results.
Two phase-3 clinical trials demonstrate a significant increase in overall survival and progression-free survival for bladder cancer patients treated with immunotherapy combinations. The studies show a 22% reduction in the risk of death compared to chemotherapy alone, providing a promising new approach for treating advanced bladder cancer.
Researchers developed a method to predict DCIS progression to invasive breast cancer using mice with human DCIS cells. The study found molecular similarities between humans and mice, including the presence of HER2 protein increasing breast cancer risk.
Researchers at the Netherlands Cancer Institute discovered a molecular key that locks cohesin rings, determining DNA shape and chromosome structure. This finding has broader implications for cell behavior, suggesting a universal mechanism for controlling DNA.
The TIL trial has demonstrated that cell therapy using patient's own immune cells is an extremely powerful immunotherapy for metastatic melanoma, with significant shrinkage of metastases in half of patients. Progression-free survival after six months was 53%, significantly better than standard immunotherapy with ipilimumab.
Researchers from the Netherlands Cancer Institute have discovered a new 'mystery gene' responsible for maturing the actin protein, a main component of the cell skeleton. The findings shed light on the complex process by which proteins are completed and functional in cells, with potential implications for understanding muscle diseases.
Researchers at the Netherlands Cancer Institute discovered that prostate cancer cells hijack the circadian rhythm to become resistant to hormone therapy. The study found that proteins regulating the circadian clock play a crucial role in tumor cell survival, offering a potential target for new treatment strategies.
A recent study published in Cell Reports Medicine reveals that a gene family is involved in immunotherapy resistance, allowing tumor cells to evade immune detection. Inhibiting this gene family, including RNF31, makes tumor cells more susceptible to immune cell destruction.
A new study predicts patient responses to immunotherapy using tumor fragments in the lab, offering hope for personalized cancer treatment. The researchers identified specific immune cell markers that can predict treatment response and resistance.
The seven European cancer centers of Cancer Core Europe have shared their experiences and measures taken to adapt to the COVID-19 pandemic. They emphasize the importance of adapting clinical activities, communication with patients, qualified personnel, and regional collaborations to ensure continuity in cancer care.
A phase II clinical trial found that immunotherapy significantly shrinks or clears tumors in patients with non-metastasized colon cancer. In the MSI subtype, all 20 patients (100%) benefited from the therapy, while 25% of those with MSS tumors also responded well.
Researchers have identified a new vulnerability in drug-resistant melanoma that can be exploited to selectively kill cancer cells. By targeting this vulnerability with vorinostat, resistant tumor cells are killed while sensitive cells remain alive.
Researchers at the Netherlands Cancer Institute discovered that PD-L1 is stabilized by protein CMTM6, making it a potential new therapeutic target for cancer treatment. This finding may also improve the prediction of treatment success in patients with current PD-L1 blockers.
Researchers developed a new approach to cancer immunotherapy by using donated immune cells to recognize and target cancer cells. The study found that adding mutated DNA from cancer cells into immune-stimulating cells from healthy donors can trigger an immune response in healthy cells, which can then be used to attack cancer cells.
Women with breast cancer who follow a physical exercise program during chemotherapy experience less fatigue, nausea, and pain. The study found that both moderate and low-intensity exercise programs significantly reduced the need for dose adjustments in chemotherapy treatment.
Breast tumors trick immune cells to produce neutrophils that block T-cell action, allowing cancer to spread. Anti-IL17 drugs already exist for inflammatory diseases, offering potential treatment for metastatic breast cancer.